Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

NANTES, France, July 19, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company will receive a €9.2 million grant from the “Projets de...
June 23, 2017 15:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer

NANTES, France, June 23, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today announced that following the recommendation by IDMC (independent experts) on the...
June 21, 2017 12:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127

NANTES, France, June 21, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announces today that the Company has received €2.597 million from Bpifrance following the...
June 15, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies (FOCIS) Conference

OSE-127 Blocks Pathological Homing of Human T Lymphocytes to Inflamed ColonEx vivo, OSE-127 Reduces Production of Gamma Interferon by Human Proinflammatory Bowel T lymphocytes in Patients’ Biopsies ...
June 14, 2017 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders

NANTES, France, June 14, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173); (Mnémo:OSE) announces that all the resolutions submitted to a vote at the Combined General...
June 12, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York

NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today announced that the Company has entered into a multi-year research collaboration on...
May 22, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists

NANTES, France, May 22, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173); (Mnémo:OSE) announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and...
May 18, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum

NANTES, France, May 18, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE) announced today that the Company will present at the upcoming “Annual Sachs...
May 15, 2017 12:15 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 15-16, 2017

NANTES, France, May 15, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company presented in oral session significant data on Selective...
April 05, 2017 02:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memory Response

NANTES, France, April 05, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE) announced today that the Company presented significant results at the AACR* meeting in...